Base de dados : MEDLINE
Pesquisa : C04.834.450 [Categoria DeCS]
Referências encontradas : 1070 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 107 ir para página                         

  1 / 1070 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28917462
[Au] Autor:Dianzani C; Paolini F; Conforti C; Riva E; Beninati E; Venuti A
[Ad] Endereço:Department of Plastic, Reconstructive and Cosmetic Surgery, Campus Bio-Medico University Hospital, Rome, Italy.
[Ti] Título:Human papilloma virus expression in immunocompetent patients with actinic keratosis: A case series.
[So] Source:J Am Acad Dermatol;77(4):770-772, 2017 10.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Antivirais/imunologia
Imunocompetência/fisiologia
Ceratose Actínica/epidemiologia
Papillomaviridae/imunologia
Infecções por Papillomavirus/epidemiologia
[Mh] Termos MeSH secundário: Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Comorbidade
Feminino
Seres Humanos
Incidência
Ceratose Actínica/imunologia
Ceratose Actínica/virologia
Masculino
Papillomaviridae/isolamento & purificação
Infecções por Papillomavirus/imunologia
Infecções por Papillomavirus/patologia
Prognóstico
Valores de Referência
Medição de Risco
Amostragem
Fatores Sexuais
[Pt] Tipo de publicação:COMPARATIVE STUDY; LETTER; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Viral)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170918
[St] Status:MEDLINE


  2 / 1070 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28756154
[Au] Autor:Vignion-Dewalle AS; Baert G; Thecua E; Vicentini C; Mortier L; Mordon S
[Ad] Endereço:Univ. Lille, INSERM, CHU Lille, U1189 - ONCO-THAI, Image Assisted Laser Therapy for Oncology, F-59000 Lille, France. Electronic address: anne-sophie.vignion@inserm.fr.
[Ti] Título:Photodynamic therapy for actinic keratosis: Is the European consensus protocol for daylight PDT superior to conventional protocol for Aktilite CL 128 PDT?
[So] Source:J Photochem Photobiol B;174:70-77, 2017 Sep.
[Is] ISSN:1873-2682
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Topical photodynamic therapy (PDT) is an established treatment modality for various dermato-oncologic conditions. In Europe, initially requiring irradiation with red light, PDT of actinic keratosis (AK) can now also be carried out with exposure to daylight that has been clinically proven to be as effective as and less painful than red light. OBJECTIVES: In this paper, we propose a comparison between the conventional protocol for Aktilite CL 128 (red light source) PDT and the European consensus protocol for daylight PDT - with the exposure is assumed to be performed during either a clear sunny day or an overcast day - in the treatment of AK with methyl aminolevulinate through a mathematical modeling. METHOD: This already published modeling that is based on an iterative procedure alternating determination of the local fluence rate and updating of the local optical properties enables to estimate the local damage induced by the therapy. RESULTS: The European consensus protocol for daylight PDT during a sunny day and an overcast day provides, on average, 6.50 and 1.79 times higher PDT local damages at the end of the treatment than those obtained using the conventional protocol for Aktilite CL 128 PDT, respectively. CONCLUSIONS: Results analysis shows that, even performed during an overcast day, the European consensus protocol for daylight PDT leads to higher PDT local damages than the efficient conventional protocol for Aktilite CL 128.
[Mh] Termos MeSH primário: Consenso
Ceratose Actínica/tratamento farmacológico
Fotoquimioterapia/métodos
Luz Solar
[Mh] Termos MeSH secundário: Relação Dose-Resposta à Radiação
Europa (Continente)
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170731
[St] Status:MEDLINE


  3 / 1070 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28711897
[Au] Autor:Оshyvalova ОО
[Ad] Endereço:STATE SCIENTIFIC INSTITUTION "SCIENTIFIC AND PRACTICAL CENTRE OF PREVENTIVE AND CLINICAL MEDICINE" OF THE STATE ADMINISTRATION, UKRAINE, KYIV, SHUPYK NATIONAL MEDICAL ACADEMY OF POSTGRADUATE EDUCATION, UKRAINE, KYIV.
[Ti] Título:Studying risk factors for skin cancer development.
[So] Source:Wiad Lek;70(3 pt 1):503-507, 2017.
[Is] ISSN:0043-5147
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: In most countries with a population of mainly European origin, non-melanoma skin carcinoma incidence rate has increased over the last decade. Understanding of what is the best way to identify people at high risk for skin cancer development will help to optimize the strategy for prevention and treatment tactics. Aim of the research involves studying risk factors for skin cancer development in patients with cutaneous squamous cell carcinoma and squamous cell carcinoma in situ (cSCC and SCCis correspondingly) and patients with actinic keratosis (AK). MATERIALS AND METHODS: we conducted a survey of patients with cSCC, SCCis and AK who had been under case follow-up at the State Scientific Institution "Scientific and Practical Centre of Preventive and Clinical Medicine" of the State Administration (hereinafter SIS) during 2014-2016.Clinical diagnosis in 100% of cases was confirmed by pathomorphological study. Statistical processing of the obtained data was performed using STATISTICA 7.0 programme. RESULTS: The questionnaire involved 129 patients, including 21(16.3%) patient with cSCC, 40 (31%) patients with SCCis, 57 (44.2%) patients with AK and 11 (8.5%) patients who had mentioned above combined pathology i.e. cSCC, SCCis and АК at the same time. Only two studied risk factors for skin cancer development were found to have influence on the skin pathology: "Not using sun-protection preparation for the skin" and "Burdened family history of thefirst level of relationship". CONCLUSIONS: In forming the risk groups for skin cancer development it is advisable to consider burdened family history and using sun-protection preparation for the skin.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/etiologia
Ceratose Actínica
Neoplasias Cutâneas/etiologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Carcinoma de Células Escamosas/epidemiologia
Feminino
Seres Humanos
Masculino
Anamnese
Meia-Idade
Fatores de Risco
Neoplasias Cutâneas/epidemiologia
Protetores Solares
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sunscreening Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170717
[St] Status:MEDLINE


  4 / 1070 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28662116
[Au] Autor:Pillon A; Gomes B; Vandenberghe I; Cartron V; Cèbe P; Blanchet JC; Sibaud V; Guilbaud N; Audoly L; Lamant L; Kruczynski A
[Ad] Endereço:Pierre Fabre Research Institute, Research & Development Center, Toulouse, France.
[Ti] Título:Actinic keratosis modelling in mice: A translational study.
[So] Source:PLoS One;12(6):e0179991, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Actinic keratoses (AK) are pre-malignant cutaneous lesions caused by prolonged exposure to ultraviolet radiation. As AKs lesions are generally accepted to be the initial lesions in a disease continuum that progresses to squamous cell carcinoma (SCC), AK lesions have to be treated. They are also the second most common reason for visits to the dermatologist. Several treatments are available but their efficacy still needs to be improved. The UV-B-induced KA lesion mouse model is used in preclinical studies to assess the efficacy of novel molecules, even though it is often more representative of advanced AK or SCC. OBJECTIVES: Here we report on a translational study, comparing the various stages of AK development in humans and in the UV-B irradiated mouse model, as well as the optimization of photograph acquisition of AK lesions on mouse skin. METHODS: Human and mouse skin lesions were analysed by histology and immunohistochemistry. Mouse lesions were also assessed using a digital dermatoscope. RESULTS: An histological and phenotypic analysis, including p53, Ki67 and CD3 expression detection, performed on human and mouse AK lesions, shows that overall AK modelling in mice is relevant in the clinical situation. Some differences are observed, such as disorganization of keratinocytes of the basal layer and a number of atypical nuclei which are more numerous in human AK, whereas much more pronounced acanthosis is observed in skin lesion in mice. Thanks to this translational study, we are able to select appropriate experimental conditions for establishing either early or advanced stage AK or an SCC model. Furthermore, we optimized photograph acquisition of AK lesions on mouse skin by using a digital dermatoscope which is also used in clinics and allows reproducible photograph acquisition for further reliable assessment of mouse lesions. Use of this camera is illustrated through a pharmacological study assessing the activity of CARAC®. CONCLUSION: These data demonstrate that this mouse model of UV-B-induced skin lesions is predictive for the identification of novel therapeutic treatments for both early and advanced stages of the disease.
[Mh] Termos MeSH primário: Modelos Animais de Doenças
Ceratose Actínica/patologia
Pesquisa Médica Translacional
[Mh] Termos MeSH secundário: Animais
Dermoscopia
Fluoruracila/uso terapêutico
Seres Humanos
Imunossupressores/uso terapêutico
Ceratose Actínica/tratamento farmacológico
Camundongos
Camundongos Pelados
Raios Ultravioleta
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170630
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179991


  5 / 1070 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28595997
[Au] Autor:Lanfredini S; Olivero C; Borgogna C; Calati F; Powell K; Davies KJ; De Andrea M; Harries S; Tang HKC; Pfister H; Gariglio M; Patel GK
[Ad] Endereço:European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff, UK.
[Ti] Título:HPV8 Field Cancerization in a Transgenic Mouse Model Is due to Lrig1+ Keratinocyte Stem Cell Expansion.
[So] Source:J Invest Dermatol;137(10):2208-2216, 2017 Oct.
[Is] ISSN:1523-1747
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:ß-Human papillomaviruses (HPVs) cause near ubiquitous latent skin infection within long-lived hair follicle (HF) keratinocyte stem cells. In patients with epidermodysplasia verruciformis, ß-HPV viral replication is associated with skin keratosis and cutaneous squamous cell carcinoma. To determine the role of HF keratinocyte stem cells in ß-HPV-induced skin carcinogenesis, we utilized a transgenic mouse model in which the keratin 14 promoter drives expression of the entire HPV8 early region (HPV8tg). HPV8tg mice developed thicker skin in comparison with wild-type littermates consistent with a hyperproliferative epidermis. HF keratinocyte proliferation was evident within the Lrig1+ keratinocyte stem cell population (69 vs. 55%, P < 0.01, n = 7), and not in the CD34+, LGR5+, and LGR6+ keratinocyte stem cell populations. This was associated with a 2.8-fold expansion in Lrig1+ keratinocytes and 3.8-fold increased colony-forming efficiency. Consistent with this, we observed nuclear p63 expression throughout this population and the HF infundibulum and adjoining interfollicular epidermis, associated with a switch from p63 transcriptional activation isoforms to ΔNp63 isoforms in HPV8tg skin. Epidermodysplasia verruciformis keratosis and in some cases actinic keratoses demonstrated similar histology associated with ß-HPV reactivation and nuclear p63 expression within the HF infundibulum and perifollicular epidermis. These findings would suggest that ß-HPV field cancerization arises from the HF junctional zone and predispose to squamous cell carcinoma.
[Mh] Termos MeSH primário: Queratinócitos/patologia
Ceratose Actínica/patologia
Glicoproteínas de Membrana/metabolismo
Neoplasias Experimentais
Células-Tronco Neoplásicas/patologia
Proteínas do Tecido Nervoso/metabolismo
Neoplasias Cutâneas/patologia
[Mh] Termos MeSH secundário: Animais
Proliferação Celular
Queratinócitos/metabolismo
Ceratose Actínica/metabolismo
Camundongos
Camundongos Transgênicos
Células-Tronco Neoplásicas/metabolismo
Papillomaviridae
Neoplasias Cutâneas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Lrig1 protein, mouse); 0 (Membrane Glycoproteins); 0 (Nerve Tissue Proteins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170610
[St] Status:MEDLINE


  6 / 1070 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28581229
[Au] Autor:Legat FJ; Wolf P
[Ad] Endereço:Department of Dermatology, Medical University of Graz, Graz, Austria.
[Ti] Título:Daylight photodynamic therapy: where and when is it possible?
[So] Source:Br J Dermatol;176(6):1440-1441, 2017 06.
[Is] ISSN:1365-2133
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Ácido Aminolevulínico
Fotoquimioterapia
[Mh] Termos MeSH secundário: Seres Humanos
Ceratose Actínica
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
88755TAZ87 (Aminolevulinic Acid)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE
[do] DOI:10.1111/bjd.15541


  7 / 1070 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28581227
[Au] Autor:Bower C
[Ad] Endereço:Department of Dermatology, Royal Devon & Exeter Hospital, Gladstone Road, Exeter, EX1 2ED, U.K.
[Ti] Título:Field treatment of actinic keratosis on the scalp.
[So] Source:Br J Dermatol;176(6):1425-1426, 2017 06.
[Is] ISSN:1365-2133
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Ceratose Actínica
Couro Cabeludo
[Mh] Termos MeSH secundário: Seres Humanos
Ceratose
Dermatoses do Couro Cabeludo
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE
[do] DOI:10.1111/bjd.15579


  8 / 1070 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28562434
[Au] Autor:Pei S; Kaminska ECN; Tsoukas MM
[Ad] Endereço:*Department of Dermatology, University of Wisconsin, Madison, Wisconsin; †Section of Dermatology, Pritzker School of Medicine, The University of Chicago, NorthShore University Health System, Skokie, Illinois; ‡Department of Dermatology, University of Illinois at Chicago, Chicago, Illinois.
[Ti] Título:Treatment of Actinic Keratoses: A Randomized Split-Site Approach Comparison of Sequential 5-Fluorouracil and 5-Aminolevulinic Acid Photodynamic Therapy to 5-Aminolevulinic Acid Photodynamic Monotherapy.
[So] Source:Dermatol Surg;43(9):1170-1175, 2017 Sep.
[Is] ISSN:1524-4725
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Actinic keratoses (AKs) are skin lesions resulting from sun exposure and carry a risk of developing into squamous cell carcinoma. Current therapies for AK eradication include topical 5-fluorouracil (5-FU) and photodynamic therapy (PDT) with topical 5-aminolevulinic acid (ALA). However, sequential therapy with 5-FU-ALA-PDT may offer improved outcome compared to ALA-PDT alone. OBJECTIVE: The purpose of this study is to compare the long-term efficacy of AK clearance by sequential therapy with 5-FU-ALA-PDT versus ALA-PDT alone. MATERIALS AND METHODS: This is a single center, randomized split-site approach study on equivalent anatomical and clinical sites. Seventeen patients were enrolled with one half of the site randomized to receive sequential 5-FU-ALA-PDT and the other side with ALA-PDT monotherapy. Total AKs were counted at baseline, 6 and 12 months. RESULTS: Median percentage reduction in AK number at 6 months for 5-FU-ALA-PDT versus ALA-PDT was 100% for 5-FU-ALA-PDT (N = 21) and 66.7% for ALA-PDT (N = 21), p = .001. Median percentage reduction in AK number at 12 months for 5-FU-ALA-PDT versus ALA-PDT was 100% for 5-FU-ALA-PDT (N = 22) and 82.6% for ALA-PDT (N = 22), p = .0002. CONCLUSION: Sequential therapy with 5-FU-ALA-PDT is more effective at AK clearance at 6 and 12 months compared to ALA-PDT monotherapy.
[Mh] Termos MeSH primário: Ácido Aminolevulínico/uso terapêutico
Fármacos Dermatológicos/uso terapêutico
Fluoruracila/uso terapêutico
Ceratose Actínica/tratamento farmacológico
Fármacos Fotossensibilizantes/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Ácido Aminolevulínico/efeitos adversos
Fármacos Dermatológicos/efeitos adversos
Quimioterapia Combinada
Estética
Feminino
Fluoruracila/efeitos adversos
Seres Humanos
Masculino
Meia-Idade
Fármacos Fotossensibilizantes/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Photosensitizing Agents); 88755TAZ87 (Aminolevulinic Acid); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170601
[St] Status:MEDLINE
[do] DOI:10.1097/DSS.0000000000001161


  9 / 1070 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28538027
[Au] Autor:Reinehr CPH; Garbin GC; Bakos RM
[Ad] Endereço:*All authors are affiliated with the Department of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
[Ti] Título:Dermatoscopic Patterns of Nonfacial Actinic Keratosis: Characterization of Pigmented and Nonpigmented Lesions.
[So] Source:Dermatol Surg;43(11):1385-1391, 2017 Nov.
[Is] ISSN:1524-4725
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Actinic keratoses (AKs) are dysplastic proliferations of keratinocytes. Studies evaluating nonfacial dermatoscopic pattern of AKs are scarce. OBJECTIVE: This study aimed to evaluate the dermatoscopic patterns of AKs located in nonfacial sites and to compare their patterns with facial lesions. MATERIALS AND METHODS: Patients with concomitant facial and nonfacial AKs were recruited to participate and evaluated by clinical and dermatoscopic images of their AKs. RESULTS: Sixty-eight patients were included in the study. A total of 258 nonfacial AKs and 68 facial AKs were analyzed. The most frequent nonfacial AK dermatoscopic structures were white opaque scales (97.3%) and erythema (57.4%). When analyzed in combination, white scales plus erythema were found in 55.4% of nonfacial AKs. Pigmented structures were observed in 22.5% nonfacial AKs. Homogeneous brown pigmentation was the most prevalent pigmented structure in nonfacial pigmented AK (pAK) (93.1%). There was a positive association between patients having concomitant pigmented facial and nonfacial AKs (p < .001). CONCLUSION: The combinations of erythema and white opaque scales or yellow opaque scales and homogeneous pigmentation are suggestive, respectively of nonpigmented and pigmented nonfacial AKs. Pigmented AKs occur concomitantly in facial and nonfacial areas.
[Mh] Termos MeSH primário: Dermoscopia/métodos
Ceratose Actínica/patologia
Pigmentação da Pele
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Dermatoses Faciais/patologia
Feminino
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170525
[St] Status:MEDLINE
[do] DOI:10.1097/DSS.0000000000001210


  10 / 1070 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28514458
[Au] Autor:Petukhova TA; Hassoun LA; Foolad N; Barath M; Sivamani RK
[Ad] Endereço:Department of Dermatology, University of California-Davis, Sacramento.
[Ti] Título:Effect of Expedited Microneedle-Assisted Photodynamic Therapy for Field Treatment of Actinic Keratoses: A Randomized Clinical Trial.
[So] Source:JAMA Dermatol;153(7):637-643, 2017 Jul 01.
[Is] ISSN:2168-6084
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Photodynamic therapy (PDT) is an effective and cosmetically favorable treatment modality for actinic keratoses (AKs). However, prolonged incubation times and pain associated with treatment are burdensome to the patient and a hindrance to widespread use of PDT as standard field therapy for AK. Objective: To evaluate efficacy and pain associated with microneedle expedited PDT. Design, Setting, and Participants: The Microneedle Photodynamic Therapy II (MNPDT-II) study was a randomized, single-blinded, split-face controlled, 2-arm clinical trial. Thirty-three participants with AK on the face were recruited in a university dermatology outpatient clinic from 2015 to 2016, and 32 participants completed the study. Interventions: Participants were randomized into 2 incubations arms, either 10-minute or 20-minute aminolevulinic acid (ALA) incubation times, after pretreatment with a microneedle roller (200 um) vs a sham roller. They were blinded to the laterality of microneedle and sham roller assignments. After incubation, they were exposed to blue light (Blu-U, Dusa Pharmaceuticals) for 1000 seconds for a total fluence of 10 J/cm2. Main Outcomes and Measures: The primary outcome was to quantitatively measure AK resolution, and the secondary outcome was to assess pain associated with microneedle pretreatment. Results: Thirty-three individuals were recruited and randomized to either the 20-minute or the 10-minute incubation arm. Thirty-two participants completed the study with a mean follow-up time of 34.5 days in the 20-minute group, and 30.2 days in the 10-minute group. For the 20-minute incubation arm, average AK clearance was 76% vs 58% on the sham side (P < .01), including 3 patients with complete clearance, although not statistically significant (P = .25). Pain assessment on the visual analog scale (VAS) during blue light illumination was not significantly different between the microneedle and sham sides (0.7 and 0.4; P = .28), respectively. For the 10-minute incubation arm AK clearance for the microneedle pretreated side was 43% compared with 38% on the sham side (P = .66). Pain during the blue light exposure was not significantly different between the microneedle and sham sides, 4.5 mm and 3.4 mm (P = .21), respectively. Conclusions and Relevance: Photodynamic therapy with microneedle pretreatment at a 20-minute ALA incubation time significantly improved AK clearance with efficacy similar to that of a conventional 1-hour ALA incubation time. The additional advantage to expedited treatment was that the procedure was virtually painless. However, expedited exposure of a 10-minute ALA incubation time did not reach significantly different AK clearance from the sham control. Trial Registration: clinicaltrials.gov Identifier: NCT02594644.
[Mh] Termos MeSH primário: Ácido Aminolevulínico/administração & dosagem
Ceratose Actínica/tratamento farmacológico
Fotoquimioterapia/métodos
Fármacos Fotossensibilizantes/administração & dosagem
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Masculino
Meia-Idade
Agulhas
Dor/epidemiologia
Dor/etiologia
Medição da Dor
Método Simples-Cego
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Photosensitizing Agents); 88755TAZ87 (Aminolevulinic Acid)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170518
[St] Status:MEDLINE
[do] DOI:10.1001/jamadermatol.2017.0849



página 1 de 107 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde